Small Molecules

Search our small molecule opportunities against novel cancer targets and pathways. We have drug discovery, pre-clinical and clinical stage opportunities available for co-development and/or licensing.

First-in-class inhibitors of Atypical Protein Kinase C (aPKC)

Opportunity for a first-in-class oncology asset, through parallel preclinical disease positioning and toxicology/phase I plan approach.

Inhibitors of Cdc7

CRUK Commercial Partnerships is seeking a partner to progress our lead compounds to clinical investigation for development of Cdc7 inhibition-based cancer therapy.

First-in-Class IKK Alpha Selective Compounds

We are seeking a co-development or licensing partner to drive candidate selection and entry into formal pre-clinical studies.

Chk2 Inhibitor Programme

We are seeking a commercial partner interested in pursuing a co-development or direct licensing arrangement.

Cancer Research Technology

You are here

Small Molecules